Long-term treatment of eosinophilic esophagitis esophagitis with budesonide

Details

Serval ID
serval:BIB_7EC4F5FE9FBA
Type
Inproceedings: an article in a conference proceedings.
Publication sub-type
Abstract (Abstract): shot summary in a article that contain essentials elements presented during a scientific conference, lecture or from a poster.
Collection
Publications
Institution
Title
Long-term treatment of eosinophilic esophagitis esophagitis with budesonide
Title of the conference
Digestive Disease Week (DDW) 2010
Author(s)
Straumann A., Degen L., Bussmann C., Beglinger C., Schoepfer A., Thalmann C., Simon H.U.
Address
New Orleans, Louisiana, United-States, May 1-5, 2010
ISBN
0016-5085
Publication state
Published
Issued date
2010
Volume
138
Series
Gastroenterology
Pages
S123
Language
english
Abstract
BACKGROUND: Eosinophilic esophagitis (EoE) is a chronic-inflammatory disease of the
esophagus, characterized by esophagus-related symptoms and a dense tissue eosinophilia,
both refractory to proton pump inhibitors. Topical corticosteroids have proven effective in
inducing clinical and histologic remission. However, a long-term strategy for the management
of this chronic disease is not yet defined.
METHODS: In a randomized, double-blind, placebocontrolled,
long-term trial, we evaluated the efficacy of twice-daily 0.25 mg swallowed
budesonide in maintaining a remission in adult EoE with prior response to induction therapy.
Pre- and post-treatment disease activity was assessed clinically, endoscopically, histologically,
by immunofluorescence and by high-resolution endosonography. The primary end point
was the ability to maintain histologic remission (<5 eos/hpf) of EoE in. Secondary end points
were the efficacy on symptom control and on tissue remodeling as well as the determination
of the safety of long-term esophageal administration of topical corticosteroids.
RESULTS: During a 50-week therapy of quiescent EoE with low-dose budesonide the esophageal
eosinophil load (ECP staining) increased from 1.1 to 29.9 eos/hpf, but under placebo the
increase was significantly larger (0.5 to 51.1 eos/hpf; p=0.01). At the end of the studyperiod,
35.7% (5/14) of the budesonide patients were in complete and 14.3% (2/14) in
partial histologic remission; with placebo no patient was in complete and 28.6% (4/14)
were in partial remission (p=0.0647). The increase of the symptom score was markedly
lower in budesonide- (0.79 to 2.29 points) than in placebo-patients (0.71 to 4.00 points;
p=0.0875). The median time to relapse of symptoms was >125 days in the budesonide and
95 days in the placebo group (p = 0.14). Measured by high-resolution endosonography, all
EoE patients had pre-treatment a highly thickened esophageal wall compared with healthy
controls (3.05±1.08 mm vs. 2.18±0.35 mm; p<0.0001). Long-term topical budesonide
reduced mainly the thickness of the superficial wall layers (mucosa, 0.75 mm to 0.45 mm;
p=0.025) whereas the response of the deeper layers was less pronounced (submucosa 1.31
to 1.08 mm; p=0.19 and muscularis 0.82 to 0.76 mm; p=0.72). Budesonide did not evoke
any mucosal atrophy.
CONCLUSIONS: This study clearly demonstrates that 1) Untreated
eosinophil inflammation results in an impressive remodeling of the esophagus; 2) A therapy
is therefore needed; 3) The high relapse rate after short-term therapy requires a long-term
management and 4) Maintenance treatment with budesonide is well tolerated and keeps
half of the patients in remission.
Create date
02/02/2011 14:05
Last modification date
20/08/2019 14:39
Usage data